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Statement of Translational Relevance 36 
This multinational study identifies genomic and immunogenetic factors with prognostic significance 37 
in splenic marginal zone lymphoma (SMZL), a rare B cell non Hodgkins lymphoma. Genomic 38 
mutations in TP53, KLF2, NOTCH2 and TNFAIP3 were found collectively in over 40% of cases and 13% 39 
utilised IGHV genes with no somatic hypermutation (SHM). TNFAIP3 mutations were associated with 40 
an increased risk of high grade transformation. IGHV genes lacking SHM, KLF2 and NOTCH2 41 
mutations were associated with shorter time to first treatment, while TP53 and MYD88 mutations 42 
were predictors of short and long overall survival, respectively. In contrast to cytogenetic and FISH 43 
data, NOTCH2 and TP53 mutations remained independent factors of outcome in multivariate 44 
analyses which included the established prognostic markers: anaemia and thrombocytopenia. 45 
Genomic and immunogenetic data have the potential to aid diagnosis, and influence the timing and 46 
choice of treatment in SMZL. 47 
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Abstract 49 
Purpose: Mounting evidence supports the clinical significance of gene mutations and immunogenetic 50 
features in common mature B-cell malignancies.  51 
Experimental Design: We undertook a detailed characterization of the genetic background of splenic 52 
marginal zone lymphoma (SMZL), using targeted re-sequencing and explored potential clinical 53 
implications in a multinational cohort of 175 SMZL patients. 54 
Results: We identified recurrent mutations in TP53 (16%), KLF2 (12%), NOTCH2 (10%), TNFAIP3 (7%), 55 
MLL2 (11%), MYD88 (7%) and ARID1A (6%), all genes known to be targeted by somatic mutation in 56 
SMZL. KLF2 mutations were early, clonal events, enriched in patients with del(7q) and IGHV1-2*04 B-57 
cell receptor immunoglobulins, and were associated with a short median time-to-first-treatment 58 
(0.12 vs. 1.11 yrs; P=0.01). In multivariate analysis mutations in NOTCH2 (HR 2.12, 95%CI 1.02-4.4, 59 
P=0.044) and 100% germline IGHV gene identity (HR 2.19, 95%CI 1.05-4.55, P=0.036) were 60 
independent markers of short time-to-first-treatment, while TP53 mutations were an independent 61 
marker of short overall survival (HR 2.36, 95% CI 1.08-5.2, P=0.03).  62 
Conclusion: We identify key associations between gene mutations and clinical outcome, 63 
demonstrating for the first time that NOTCH2 and TP53 gene mutations are independent markers of 64 
reduced treatment-free and overall survival, respectively. 65 
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Introduction 67 
Splenic marginal zone lymphoma (SMZL) is a rare chronic B-cell lymphoproliferative disorder that 68 
predominantly affects elderly patients and involves the spleen, bone marrow, and usually the 69 
peripheral blood (1). The diagnosis is based on a combination of clinical, morphological, 70 
histopathological and immunophenotypic data, that serve to distinguish it from other splenic 71 
lymphomas (1). Additional distinctive biological features of SMZL include a remarkable bias to the 72 
expression of clonotypic B-cell receptors (BcR) utilizing the IGHV1-2*04 gene and frequent deletions 73 
of chromosome 7q (2,3). The median survival of SMZL is around 10 years; 70% of patients require 74 
treatment for progressive, symptomatic disease and 5-10% undergo transformation into large B-cell 75 
lymphoma. Response rates to splenectomy, single agent Rituximab and Rituximab plus 76 
chemotherapy are high but approximately 40% of patients develop progressive disease within 5 77 
years (4,5). 78 
Easily measured, non disease-specific, parameters such as haemoglobin, platelet count, LDH, serum 79 
albumin and the presence of extrahilar lymphadenopathy have prognostic significance in 80 
multivariate analysis for overall survival and have led to the introduction of scoring systems and a 81 
prognostic index (6-8). In contrast, the value of biomarkers to predict outcome is much less clear. 82 
Unmutated immunoglobulin heavy variable (IGHV) genes, karyotypic complexity, TP53 loss/mutation 83 
alone or in combination with del(8p), and del(14q) have all been suggested to have an adverse 84 
prognostic significance in univariate analyses but none have been confirmed in multivariate analyses 85 
(3,9-13). Candidate gene screening and more recently, whole genomic or whole exomic sequencing 86 
(WES) studies in small patient cohorts have identified recurrent mutations of genes involved in 87 
NOTCH, BcR, Toll-like receptor (TLR) and NF-κB signaling pathways, chromatin remodelling and the 88 
cytoskeleton (14-17). However, targeted resequencing of larger patient cohorts has resulted in 89 
conflicting data on the incidence and prognostic significance of NOTCH2 mutations while little is 90 
known about the clinical significance of other gene mutations (14,15).  91 
These observations highlight the need for larger studies to determine a more comprehensive picture 92 
of the clinical significance of gene mutations in SMZL. Accordingly, using a targeted re-sequencing 93 
approach, we screened for mutations in the largest cohort of well-characterised SMZL cases 94 
published to date [n=175] and identified a number of gene mutations that contribute to reduced 95 
outcome in SMZL. Most notably we demonstrate for the first time that previously known gene 96 
mutations (NOTCH2 and TP53) are independent markers of poor survival. 97 
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Material and methods 98 
Patients and samples 99 
Table 1 describes our cohort of 175 SMZL patients from eight centres across Europe, all meeting 100 
established diagnostic criteria (18). The mean time from diagnosis to sampling was 3.2 years (0-24, 101 
SD = 4.7). Mantle cell lymphoma (MCL) was excluded in CD5+ve cases using FISH and conventional 102 
cytogenetics. Splenic lymphoma/leukemia unclassifiable (SLLU) was precluded either by splenic 103 
histopathology or by omission of SLLU-variant cases with distinctive cytology, such as those with 104 
splenic diffuse red pulp lymphoma (SDRL). Each transformation event was diagnosed histologically. 105 
Informed patient consent was obtained according to the declaration of Helsinki and the study was 106 
ethically approved by the local REC.  107 
DNA was extracted from either peripheral blood [n=135], bone marrow [n=22], spleen [n=17] or 108 
lymph nodes [n=1]. Germline DNA was obtained from buccal cells or sorted T cells [n=25]. The 109 
Sequential DNA samples from 9 cases either diagnosed as clonal lymphocytosis of marginal-zone 110 
origin (19) [CBL-MZ, n=1] or SMZL [n=8] (mean of 4.3 yrs between samples, Supp Table 1) were 111 
evaluated to investigate the clonal evolution of key gene mutations. 112 
Haloplex Re-sequencing and Sanger validation 113 
189 DNA samples from 175 SMZL cases were analysed with Haloplex Target Enrichment system 114 
(Agilent Technologies) that enriched 2.39 Mb of genomic DNA for the coding regions of 49 genes 115 
known to be targeted by somatic mutations in SMZL, and an additional 719 genes with a postulated 116 
role in the pathophysiology of SMZL or other chronic B-cell lymphoproliferative disorders (Supp 117 
Methods and Supp Table 2). Independent analysis was performed by the University of Southampton 118 
and Uppsala University to allow the identification of high-confidence variants in our cohort (Supp 119 
Methods). 120 
Using conventional Sanger sequencing, we validated 86 variants identified in a number of genes 121 
using the experimental conditions and primers described in Supp Table 3. Furthermore, we 122 
independently screened NOTCH2 exon 34 in 145/175 SMZL, using primers from Rossi et al (14) . 123 
Statistical analysis 124 
Statistical analysis was performed using SPSS (v20). Time-to-first-treatment (TTFT), Event-free (EFS) 125 
and Overall survival (OS) as defined in the Supp Methods. Our cohort has 81% power to detect an 126 
Overall Survival 0.5 Hazard Ratio associated with NOTCH2 mutations present in 26% of patients (as 127 
observed (14)). Results were determined to be statistically significant at the 5% level. 128 
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Results 130 
Overview of re-sequencing data 131 
The mean re-sequencing depth across our gene panel was 297-fold (range 129-702). More than 85% 132 
of all bases were covered at >50-fold. The analysis described herein, focuses on the biological and 133 
clinical importance of key recurrently mutated genes (Figure 1A) known to be somatically acquired in 134 
SMZL based on previously published data (14-17,20-22). For our data on other gene mutations, 135 
whilst many are annotated in the COSMIC database they could not be confirmed as somatically 136 
acquired due to the lack of patient germ-line material and were not taken forward for analysis 137 
(Detailed in Supp Table 4). This lack of germ-line material is not unexpected in an international 138 
retrospective cohort of rare tumours such as SMZL.  139 
In our cohort, we identified recurrent mutations, at suitable frequency for accurate clinical 140 
correlations, in TP53 [n=26 cases], KLF2 [n=21], MLL2 [n=20], NOTCH2 [n=17], TNFAIP3 [n=13], 141 
MYD88 [n=12], ARID1A [n=10], NOTCH1 [n=10] and CREBBP [n=9] (Figure 1A and B, Supp Figure 1). 142 
For validation, we employed Sanger sequencing and confirmed the presence of 86/86 selected 143 
variants in these genes and we showed 99% concordance between our Haloplex and Sanger 144 
sequencing of NOTCH2 exon 34 (Supp Table 5). Furthermore, the Haloplex analysis of paired 145 
tumour/normal DNA samples [n=14], showed the presence of somatically acquired mutations in 146 
these genes [n=77] and, critically, no germ-line variants were identified in the genes we focus on 147 
herein (Supp Table 6). Therefore, our analytical data supports the somatic origin of mutations within 148 
these recurrent genes.  149 
Mutation patterns and evolution 150 
To obtain insight into the genomic context of these gene mutations, we submitted our data to two 151 
analytical packages. Firstly, we searched for pairwise gene correlations and mutually exclusive 152 
relationships between our ‘known somatic’ mutated genes using the mutation relation test (MRT, 153 
Genome Music) (23). There are 11 and 13 significant MRT co-occurring and mutually exclusive 154 
relationships between mutated genes, respectively (considering only relationships with P<0.001, 155 
Figure 1C), that demonstrated the following classes of gene mutation relationships: (1) a single and 156 
distinct independent gene mutation event, such as MYD88, where a mutation is invariably observed 157 
as an isolated event; (2) the presence of cancer drivers that have many mutually exclusive 158 
relationships, such as NOTCH2, TP53 and TNFAIP3, and (3) a group of genes such as KLF2 and ARID1A 159 
that have more co-occurring relationships, thus suggesting a synergistic function to promote 160 
tumorigenesis.  161 
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Secondly, we studied clonal evolution in SMZL, by differentiating between early, clonal events, and 162 
later, subclonal mutations. In order to do this, we initially performed integrative analysis of our 163 
Haloplex re-sequencing and SNP6 copy number data from our seven published WES SMZL cases (17), 164 
employing the ABSOLUTE algorithm (24) (Supp Figure 2). Using this approach, all our initial cases 165 
harboured a diploid genome, so we extended this analysis to include an additional 38 samples 166 
without copy number data but with purity information available from FACS analysis. Using this 167 
approach we were able to classify clonal or subclonal mutation in KLF2, NOTCH2, TP53, CREBBP and 168 
TNFAIP3 (Figure 2A and 2B).  169 
To extend this single time-point bioinformatics analysis, we also analysed a second DNA sample 170 
preceding or subsequent to SMZL diagnosis in 9 patients. For this analysis, we again only focused on 171 
variation in genes known to be targeted by somatic mutations in SMZL. We identified 12 variants, 172 
and after accounting for tumour purity, these data are outlined in Supp Table 1 and Figure 2C. Whilst 173 
the number of mutations per case was insufficient for comprehensive analysis, the following 174 
observations could be made: 1) 3 patients harboured mutations that remained fully clonal over the 175 
two timepoints (ARID1A [n=1] and CREBBP [n=2]) which supports the ABSOLUTE data for these 176 
genes, 2) 6 cases contained seven mutations where the normalized VAF increased over time, 177 
supporting the hypothesis that these genes are important in driving the disease, including four 178 
patients with TP53 mutations that acquire a deletion of 17p (isochromosomes 17q) at the second 179 
timepoint (Figure 2C), and 3) three patients displayed either a mutation that became undetectable at 180 
timepoint 2 (TNFAIP3 and NOTCH2), or one that remained at a low VAF (NOTCH2, 0.04% allele 181 
frequency), even with a concomitantly emerging TP53 mutation (Supp Table 1). 182 
Biologically significant mutations in SMZL 183 
KLF2, or Krüppel-like factor 2, mutations were detected in 21/175 cases (12%, Figure 1A) and were 184 
distributed across the entire protein, with a cluster in the C2H2 domain (C terminus). A Q24X variant 185 
was identified in three patients, suggesting the presence of mutation hotspots. Mutations were often 186 
(43%) stop-gains or frame-shift variants (Figure 1B), suggesting an impact on protein function. All 187 
mutations tested were somatically acquired (n=9). From our ABSOLUTE analysis, all 11 mutations 188 
were defined as clonal (Figure 2B), and other recurrently mutated genes present in these cases were 189 
estimated to have lower CCFs than KLF2 (e.g. NOTCH2 and TNFAIP3, Figure 2B). KLF2 mutations were 190 
significantly associated with del(7q) (53% vs. 11%; P=0.001), IGHV1-2*04 gene usage (50% vs. 7%; 191 
P<0.001), and gene mutations including NOTCH2, TNFAIP3 and ARID1A (all P<0.001). Together, these 192 
observations suggest that the potential cell survival advantage provided by an early KLF2 mutation 193 
allows the acquisition of additional functionally synergistic gene mutations to promote 194 
tumourigenesis (Figure 1C).  195 
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We independently screened NOTCH2 by Haloplex (mean gene coverage of 572-fold) and direct 196 
Sanger sequencing of exon 34, and identified 18 mutations in 17 patients, a frequency of 10% in our 197 
cohort (Figure 1A). We manually examined the NOTCH2 sequence reads and found no evidence of 198 
any additional mutations below the resolution of our variant calling algorithm. As expected, the 199 
mutations were nonsense [n=9], frameshift [n=7] and missense [n=2] principally targeting the TAD 200 
and PEST domain encoded by exon 34 (Figure 1B). Several of our mutations (R2360*, R2400*) have 201 
been previously reported to result in over-expression of the Notch2 protein and active signalling (14). 202 
NOTCH2 mutations were classified as sub-clonal or clonal (Figure 2A). We also identified NOTCH1 203 
mutations [n=10], several of which were truncating frameshift indels [n=2, P2514fs*4] or stopgain 204 
mutations [n=2] in exon 34. 205 
We identified recurrent mutations in MYD88 [12/175 cases, 7%] and TNFAIP3 [13/175 cases, 7%], 206 
genes involved in Toll-like receptor and NF-κB signalling. Of the 12 MYD88 mutations, 7 and 2 were 207 
the gain-of-function L265P or S219C variants, respectively (25). Mutations in MYD88 were single and 208 
distinct events, mutually exclusive from mutations in TP53 and NOTCH2. Twenty-one TNFAIP3 209 
mutations were identified in 13 patients (Figure 1B), 15 of which would result in truncation of the 210 
A20 protein. One of these mutations (E361X) has been shown to abrogate the ability of A20 to 211 
negatively regulate NFKB-signalling (26). Mutations co-existed with KLF2 (P<0.001) mutations but 212 
showed a reverse association with NOTCH2 (P<0.001) and TP53 (P<0.001).  213 
Mutations of TP53 and ARID1A, both involved in cell cycle control and DNA damage response, were 214 
identified in 26/175 (16%) and 10/175 (6%) patients, respectively. We defined 28 missense [n=18], 215 
nonsense [n=5], frameshift [n=2] and splicing [n=3] TP53 mutations, largely annotated in COSMIC 216 
(27/28, Figure 1B), in 26 patients who tended to have deletions of 17p (P=0.003) and a complex 217 
karyotype (P<0.001, Figure 1C). Finally, we confirm our previous study by demonstrating recurrent 218 
mutations in CREBBP [n=9] (17). All our CREBBP mutations appear to be early genetic events as they 219 
were classified as fully clonal (Figure 2A) akin to the situation in follicular lymphoma (27); two of our 220 
mutations were the Y1450C variant previously identified in DLBCL, which has been shown to 221 
compromise the protein’s ability to acetylate BCL6 and p53 (28). 222 
Clinical significance of mutations in SMZL 223 
Initially we looked for associations between gene mutations and clinical and laboratory features 224 
measured routinely in clinical practice (Figure 3A). Patients with KLF2 and NOTCH2 mutations were 225 
at higher risk of receiving treatment including splenectomy (OR=4.51, 95%CI 1.68-12.10; P=0.002 & 226 
OR=1.16, 95%CI 1.08-1.25; P=0.007). Histological evidence of transformation to large B-cell 227 
lymphoma was reported in 19/175 (11%) patients; these patients were more likely to have 100% 228 
germline IGHV gene identity (40% vs. 10%, P=0.04) and exhibited a significantly shorter overall 229 
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survival (9.0 vs 16.5 yrs; P=0.04) in comparison to non-transformed cases. The only mutated gene 230 
associated with transformation was TNFAIP3 (32% vs. 4%, P=0.002). 231 
Follow-up outcome data were available for 164, 117 and 169 patients for TTFT, EFS and OS, 232 
respectively. First, we demonstrated the clinical relevance of our cohort by testing for the prognostic 233 
significance of previously documented clinical and laboratory features (Table 2). We then performed 234 
univariate analysis of the gene mutations against TTFT, EFS and OS (Table 2). Genes associated with 235 
reduced TTFT were; 1) KLF2 (HR 1.93, 95%CI 1.16-3.32, P=0.01) where wild-type and mutant patients 236 
exhibited median TTFT of 1.11 and 0.12 years, respectively, and 2) NOTCH2 (HR 2.13, 95%CI 1.26-237 
3.58, P=0.003) where wild-type and mutant patients exhibited median TTFT of 0.94 and 0.09 years, 238 
respectively (Figure 3B and C). Gene mutations associated with shorter EFS included TP53 (HR 2.17, 239 
95%CI 1-4.74, P=0.05) with median EFS of 3.11 and 0.98 years for wild-type and mutated patients, 240 
respectively. Finally, we tested the impact of gene mutations on OS and showed reduced survival for 241 
TP53 (HR 2.16, 95%CI 1.05-4.42, P=0.032) mutations with a median OS of 12.21 and 16.03 years for 242 
mutant and wild-type cases, respectively, and the reverse for MYD88 mutated individuals (HR 0.04, 243 
95%CI 0.01-2.48, P=0.02) (Figure 3D and E). 244 
NOTCH2 and TP53 mutations were independent risk factors for reduced TTFT and OS 245 
Those gene mutations shown to be associated with reduced outcome in univariate analysis were 246 
tested using multivariate Cox proportional hazard analysis. Along with the presence of gene 247 
mutations, other variables included in the analysis were age at diagnosis, haemoglobin levels, 248 
platelets and lymphocyte counts. We developed these models for TTFT, EFS and OS as they 249 
permitted the relative prognostic value of gene mutations to be assessed in a large, informative 250 
group of patients in the context of the most available clinical data (Table 3). Our multivariate EFS 251 
model identified age at diagnosis, lymphocyte count and low platelet count as independent risk 252 
factors, however TP53 became non-significant in this analysis. We show that in addition to 253 
haemoglobin levels, both NOTCH2 (HR 2.12, 95%CI 1.02-4.4, P=0.044) and 100% germline IGHV gene 254 
identify (HR 2.19, 95%CI 1.05-4.55, P=0.036) are independent risk factors for TTFT. Furthermore, we 255 
show that the presence of TP53 mutation is an independent risk factor for OS (HR 2.36, 95%CI 1.08-256 
5.20, P=0.03). 257 
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Discussion 259 
The primary aim of this study was to determine the clinical significance of somatically acquired gene 260 
mutations in SMZL, identified in the current and previously reported studies (14-17,22). Notably, we 261 
were able to identify key associations between gene mutations and clinical outcome, demonstrating 262 
for the first time that NOTCH2 and TP53 gene mutations are independent markers of poor outcome.  263 
The main strengths of the present study were the cost-effective resequencing approach which 264 
enabled screening of a large number of candidate genes at high sequencing depth and, most 265 
importantly, the size of the cohort in a rare lymphoma, enabling us to overcome limitations befalling 266 
previous studies evaluating the clinical significance of clinical and genetic biomarkers in SMZL. 267 
Indeed, the lack of a treatment naïve clinical trial cohort, historical use of splenectomy for diagnosis, 268 
inclusion of non-splenectomised cases who might have SLLU and the indolent nature of the disease, 269 
where in an elderly population many patients die from unrelated causes, all underline the need for 270 
caution in interpreting outcome data in SMZL. We sought to minimize the effect of these factors in a 271 
number of ways: (1) by confining the study to centres with expertise in SMZL, we could ensure expert 272 
diagnostic review especially for cases diagnosed prior to the currently-accepted diagnostic criteria, 273 
(2) treatments included a limited range of modalities, predominantly splenectomy, alkylating agents 274 
and rituximab, and splenectomy was considered to be a therapy regardless of the indication (Supp 275 
Table 7), and (3) the use of multiple survival endpoints enabled the impact of prognostic markers on 276 
disease biology as well as the overall survival of an elderly patient cohort to be assessed.  277 
In additional to confirming the presence of mutations in TP53, and in genes involved in NOTCH, BcR, 278 
TLR, NF-κB signaling and in chromatin modifiers (14-17,22), we identified recurrent heterozygous 279 
inactivating mutations in KLF2, a member of the Krüppel-like family of transcription factors with roles 280 
in cell differentiation, proliferation, activation and trafficking (29), in 12% of analyzed cases. KLF2 was 281 
included in our re-sequencing experiments due to reanalysis of our published WES data (17), that 282 
showed evidence of mutations in 4/7 cases in spite of the low sequence read-depth present at this 283 
locus. During the preparation and submission of this manuscript, two studies independently 284 
identified recurrent KLF2 mutations in SMZL, at a frequency higher than in our study (22,30), which is 285 
likely to be a reflection of the patient cohort analyzed in our current study, as we identified a lower 286 
frequency of del(7q) and IGHV1-2*04 in our cohort, compared to other large studies (3,22). 287 
Interestingly, in mice, KLF2 deficiency is associated with a failure to maintain B-1 B cells, expansion of 288 
the marginal zone B-cell pool and expression of marginal zone characteristics by follicular B cells (31-289 
33). These observations may reasonably be considered as indicating a role of KLF2 mutations in the 290 
natural history of SMZL, an argument also supported by their significant enrichment among SMZL 291 
cases with clonotypic BcR utilizing the IGHV1-2*04 gene. This alludes to acquisition and/or selection 292 
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of KLF2 mutations in a context of particular signaling via specific BCRs with distinctive 293 
immunogenetic features, similar to what has been observed in other B-cell malignancies, most 294 
notably in stereotyped subsets of CLL (34). In 11 cases we were able to study the clonal architecture 295 
of KLF2 mutations: in each case the KLF2 mutations were clonal and were associated with other 296 
subclonal mutations, often involving other clinically significant genes such as NOTCH2 and TNFAIP3. 297 
The invariable association of clonal KLF2 mutations with other mutations involving different 298 
pathways, and deletions of 7q suggests that the former may have a pro-survival function and 299 
additional mutations may be necessary for disease progression. It will be of interest to determine the 300 
incidence of KLF2 mutations and genomic complexity in cases of clonal B-lymphocytosis of marginal-301 
zone origin (CBL-MZ) (19), especially in those cases progressing to SMZL.  302 
Consistent with the role of the NOTCH2-Delta-like 1 ligand pathway in normal marginal zone 303 
development (35), and the previously reported finding of NOTCH2 mutations in SMZL (14,15), we 304 
found recurrent mutations in exon 34 of NOTCH2 in 10% of cases. This compares to an incidence of 305 
21% (14), 25% (15) and 7% (16) in previously reported series, probably reflecting differences in 306 
sample size and cohort composition. We also detected recurrent mutations in other NOTCH pathway 307 
genes including NOTCH 3 and 4 and SPEN. However, their role in the pathogenesis of SMZL is unclear 308 
so we have not focused on them specifically.  309 
We evaluated the prognostic significance of somatically acquired mutations on TTFT, EFS and OS. 310 
Short TTFT was associated with mutations in KLF2, NOTCH2 and ARID1A; short EFS with mutations in 311 
TP53; and, short OS with mutations in TP53, whereas MYD88 mutations were associated with a 312 
longer OS. Although the study by Rossi et al indicated that NOTCH2 mutations were associated with a 313 
prolonged 5-year OS and progression-free survival following first line treatment (14), our data based 314 
on a substantially larger cohort shows that NOTCH2 mutation are linked to reduced outcome, an 315 
observation corroborated by Kiel et al who also noted an association with shorter time from 316 
diagnosis to either relapse, transformation or death, albeit in a much smaller cohort of SMZL cases 317 
[n=46] (15). Additional studies of larger patient cohorts will be required to validate the clinical 318 
importance of NOTCH2 mutations. Cases with a MYD88 mutation exhibited longer OS and 319 
comparable clinical and laboratory features to other cases with SMZL apart from a higher incidence 320 
of low level IgM paraproteins, detected in 8/9 cases with available data. The poor prognostic 321 
significance of TP53 mutations is consistent with previously reported data on TP53 abnormalities. 322 
Our multivariate analysis demonstrated for the first time in SMZL that both genetic and 323 
immunogenetic parameters retained prognostic significance in a model that included age, 324 
haemoglobin, platelet count and lymphocyte count. We chose to base our multivariate analysis on 325 
the study of Salido et al, as this is the only large study to include base-line clinical variables with 326 
chromosomal features (3). While the independent prognostic significance of age, anaemia and 327 
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thrombocytopenia were expected and consistent with many previous studies, the biological basis for 328 
the impact of a lymphocyte count of < 4x109/l, noted in an early (36) but not in more recent studies 329 
(3,37), requires further investigation. Interestingly, our study suggests that gene mutations, such as 330 
those targeting NOTCH2 and TP53 have more clinical utility than cytogenetic features, such as 331 
karyotypic complexity, 14q aberrations and TP53 deletions that did not retain prognostic significance 332 
in previous reports (3). Specifically, NOTCH2 and truly unmutated IGHV genes (but not unmutated 333 
IGHV genes using a 98% cut-off) were independent markers of TTFT and TP53 of OS. Given the 334 
historical use of splenectomy to both diagnose and treat SMZL patients, our associations with TTFT 335 
should be considered with a note of caution.  336 
Since transformation to a high grade lymphoma is usually associated with resistance to treatment 337 
and very poor survival, we were also interested to see if any genomic abnormalities were associated 338 
with an increased risk of transformation, as noted for NOTCH1 mutations in CLL (38). In our study, 339 
TNFAIP3 mutations together with truly unmutated clonotypic IGHV genes were all found at a higher 340 
frequency in cases that subsequently transformed. Further studies comparing the genomic landscape 341 
of paired chronic phase and clonally-related transformed samples, as performed in CLL and FL 342 
(27,39), will be required to determine the drivers of transformation.  343 
In summary, we show that gene mutations and immunogenetic features have prognostic significance 344 
in a large and well-characterized cohort of patients with SMZL. Additional studies will be required to 345 
confirm our findings and to determine the functional consequences of these mutations, the 346 
incidence and importance of copy number and epigenetic abnormalities in gene silencing and the 347 
clinical value of mutation screening in the differential diagnosis and management of SMZL.  348 
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Figure 1. Distribution of recurrent gene mutations across patients, gene mutation maps and gene 470 
by gene associations for 175 SMZL cases. 471 
(A) Heatmap of the distribution of gene mutation in our cohort 472 
(B) Schematic diagram of the protein targeted by key mutations in SMZL, with their key functional 473 
domains. The symbols and colour denote the type of mutation. Mutations annotated in COSMIC v68 474 
database are in bold text. 475 
(C) Associations between genetic and immunogenetic features of our SMZL cohort. Shows the 476 
pairwise associations amongst significantly mutated genes, genetic and immunogenetic features 477 
(labelled as ‘Genomic Feature’) across 175 SMZL cases. Genes are annotated within key pathways 478 
known to be important in the pathogenesis of mature B-cell malignancies. The number of mutations 479 
(n) for each gene mutation in the analysis is shown. An association is shaded based on the 480 
significance and only gene by genomic feature (top matrix) and gene by gene (bottom matrix) 481 
associations with a p-value of <0.01 (Chi-squared/Fisher’s exact test) or <0.001 (Mutation Relation 482 
Test, Genome MuSiC analysis) are included, respectively. 483 
Figure 2. Clonal distribution and temporal analysis of gene mutations in SMZL. 484 
(A) Shows the distribution of the estimated proportion of tumour cells harbouring a mutation in 45 485 
patients, based on the availability of purity information. Genes are displayed from left to right 486 
showing genes displaying more clonal and subclonal mutations, respectively, by using a binomial 487 
distribution based on the alternative allele read count, the total read count from cancer cells and an 488 
expected variant allelic fraction (VAF) of 0.45. For each gene, the bone-and-whisker plots show the 489 
adjusted ratio of observed VAF divided by the 50% of the purity estimate derived from CD19+ FACS 490 
data. The number of cases (n) for each gene mutation in the analysis is shown (bottom). (B) Shows 491 
the presence of clonal KLF2 mutations in five SMZL patients with matched deep re-sequencing and 492 
SNP6 data available. No KLF2 gene deletions were identified by SNP6 copy number data analysis. For 493 
each cases the cancer cell fraction (CCF) derived with the ABSOLUTE algorithm is shown for the KLF2 494 
variant and co-occurring mutations. This approach estimates the cancer cell fraction (CCF) 495 
harbouring a mutation by correcting for sample purity and local copy number changes, where 496 
mutations are classified as clonal if the CCF was >0.95 with a probability >0.5, and subclonal 497 
otherwise (40). (C) Temporal re-sequencing analysis of sequential time points in cases showing clonal 498 
expansion of gene mutations (7 of 12 mutations in 9 patients). The Y-axis shows the VAF for a given 499 
mutation after accounting for tumour purity. 500 
Figure 3. The clinical significance of gene mutations in SMZL. 501 
(A) Shows the associations between the presence of gene mutations and clinical features. Where 502 
possible genes are annotated within key pathways known to be important in the pathogenesis of 503 
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mature B-cell malignancies. The number of mutations (n) for each gene mutation in the analysis is 504 
shown. An association is shaded based on the significance and only associations with a p-value of 505 
<0.05 are included (Chi-squared/Fisher’s exact test). (B) and (C) show KM plots for time to first 506 
treatment for patients with KLF2 and NOTCH2 mutations, respectively. (D) and (E) show overall 507 
survival KM plots for patients with TP53 and MYD88 mutations, respectively. For each KM Plot, the 508 
grey and black lines identify the wild-type and mutated patient groups, respectively. The P values are 509 
derived from Kaplan-Meier analysis with a log-rank test and median survival times with 95% 510 
confidence intervals. 511 
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Table1: Patient Characteristics 
Variable Definition N % 
Number of Patients SMZL diagnosis 175 100% 
Age at Diagnosis mean (range) 68 (36-90)  
IGHV genes IGHV1-2*04 16 13% 
 not IGHV1-2*04 108 87% 
del(7q) status from karyotype del(7q) 17 19% 
 normal 74 81% 
Surface CD5 FACS result CD5+ 40 27% 
 CD5- 108 73% 
WBC mean (range) (x109/L) 20 (0.5-158)  
Hb  <12 g/dl 73 44% 
 ≥12 g/dl 93 56% 
Lymphocyte count  <4x109/L 41 27% 
 ≥4x109/L 110 73% 
Platelets <100x109/L <100x109/L 30 18% 
 ≥100x109/L 134 82% 
high-risk FISH results del(17p) 10 33% 
 normal 20 67% 
Splenectomy YES 55 34% 
 NO 109 67% 
Transformation to large cell lymphoma YES 19 17% 
 NO 91 83% 
TTFT status treated (inc. Splenectomy) 122 74% 
 Untreated 42 26% 
Event-Free Survival status Event (Death, transformation, 
2nd Tx) 
52 44% 
 No Event 65 56% 
Status (Alive or Dead at last followup) Dead 43 25% 
  Alive 126 75% 
Footnote: Complex Karyotype was defined as ≥2 cytogenetically-visible clonal alterations; Tx: treatment 
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Table 2: Univariate survival analysis of recurrently mutated genes 
   Variable  Description Total Events Median 
(yrs) 
95% CI HR 95% CI P-value
TTFT KLF2 mutated 20 18 0.12 0.0-0.24 1.93 1.16-3.23 0.01 
 unmutated 140 100 1.11 0.0-2.28   
NOTCH2 mutated 17 17 0.09 0.0-0.22 2.13 1.26-3.58 0.003
 unmutated 143 101 0.94 0.0-2.03   
Hb <12 g/dl 70 63 0.1 0.04-0.17 2.75 1.87-4.02 <0.001
 >12 g/dl 84 51 2.73 0.0-7.14   
Lymphocytes <4 x 109/l 40 33 0.15 0.07-0.24 1.76 1.16-2.68 0.007
 >4 x 109/l 101 69 1.43 0.50-2.37   
IGHV identity 100% 12 11 0.14 0.0-0.38 2.06 1.07-3.74 0.027
 < 100% 78 50 1.98 0.98-2.99   
EFS TP53 mutated 15 8 0.98 0.04-12.22 2.17 1.00-4.74 0.05 
 unmutated 84 32 3.11 2.35-6.20   
Age >65 yrs 53 26 6.82a 4.45-9.20 2.09 1.07-4.08 0.028
 <65 yrs 45 14 12.69a 9.19-16.18   
Platelet count < 100 x 109/l 19 11 2.92 2.03-3.80 1.99 0.98-4.02 0.052
  > 100 x 109/l 78 28 6.91 4.47-9.34     
OS TP53 mutated 26 10 12.21 5.28-19.14 2.16 1.05-4.43 0.032
 unmutated 134 33 16.03 14.64-17.43   
MYD88 mutated 12 0 -b -b -c -c 0.02d
 unmutated 148 43 -   
Age >65 yrs 103 37 10.36a 9.0-11.76 6.37 2.55-15.87 <0.001
 <65 yrs 56 6 22.65a 19.38-25.91   
Hb <12 g/dl 68 24 9.01 2.90-15.12 2.69 1.45-4.99 0.001
 >12 g/dl 87 18 16.35 14.99-17.70   
Footnote: Log-Rank P-values. a Mean survival value as median not reached. b No events in MYD88 mutated cases 
and median survival times not presented, follow-up time ranged from 1.25 to 19.9 years. c HR and 95% CI 
cannot be reliable calculated as there are no events in MYD88 mutated group. d Log-Rank P-value for Chi-
squared value reported for the MYD88 OS Kaplan-Meier analysis (See Figure 3E). 
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Table 3: Multivariate survival analysis of recurrently mutated genes 
Variable TTFT
HR 95% CI P-Value
Hb<12g/dl 2.28 1.32-3.96 0.003 
IGHV 100% identity 2.19 1.05-4.55 0.036 
NOTCH2 2.12 1.02-4.40 0.044 
  EFS
  HR 95% CI P-Value
Plts<100x109L 3.75 1.68-8.41 0.001 
Lymphocytes <4x109L 0.41 0.17-0.96 0.04 
Age at diagnosis <65yrs 0.45 0.21-0.96 0.038
  OS
  HR 95% CI P-Value
Hb<12gdl 2.18 1.12-4.23 0.02 
Lymphocytes <4x109L 2.35 1.11-4.97 0.03 
Age at diagnosis <65yrs 0.09 0.03-0.27 <0.001 
TP53 2.36 1.08-5.20 0.03 
Footnote: TTFT Multivariate: 83 cases with 56 events; 92 cases with 
missing data. EFS Multivariate: 82 cases with 35 events; 93 cases with 
missing data. OS Multivariate: 134 cases with 38 events; 38 cases with 
missing data. Backwards-step regression was employed, including the 
following clinical variables (Hb<12gdl, Plts<100x109L, Lymphocytes 
<4x109L, Age at diagnosis <65yrs) and the representative gene status 
variables significantly associated with treatment, event and survival 
outcome in univariate analysis (Table 2). The TTFT model also included 
IGHV 100% identity, KLF2 and NOTCH2 mutation status. EFS and OS also 
included TP53 mutation status. Variables removed from the backwards-
step regression are not shown. 
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